Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1015821210841 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inpatient management of gout: we are still failing.
J Rheumatol
January 2025
LKS: Rheumatologist, MBChB, FRACP, PhD, Department of Rheumatology, Immunology and Allergy, Rheumatology Registrar Te Whatu Ora Waitaha, New Zealand and Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
Objective: Despite effective treatment, gout is poorly managed. The aim of this study was to determine rates of serum urate (SU) testing and allopurinol dose adjustment in patients on allopurinol admitted to Christchurch based hospitals.
Methods: The hospital electronic prescribing and administration (ePA) system was used to identify patients on allopurinol during hospital admissions from March 2016-March 2023.
Antibody dynamics in dogs submitted to different canine visceral leishmaniasis treatment protocols.
Rev Bras Parasitol Vet
January 2025
Programa de Pós-graduação em Medicina Veterinária, Laboratório de Doenças Parasitárias, Departamento de Medicina Veterinária Preventiva, Universidade Federal de Santa Maria - UFSM, Santa Maria, RS, Brasil.
This study evaluated dynamics of antibodies in dogs treated for canine visceral leishmaniasis (CVL). Twenty-one dogs naturally infected by Leishmania spp. were grouped based on the treatment protocol: G1 (n=4) received allopurinol; G2 (n=10) allopurinol with miltefosine; and G3 (n=7) allopurinol, miltefosine and Leish-Tec® vaccine.
View Article and Find Full Text PDFDrug classes associated with the development of fulminant type 1 diabetes: a retrospective analysis using the FDA adverse event reporting system database.
Expert Opin Drug Saf
January 2025
Department of Endocrinology, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Background: Fulminant type 1 diabetes mellitus (FT1DM) is a severe subtype of type 1 diabetes characterized by rapid onset, metabolic disturbances, and irreversible insulin secretion failure. Recent studies have suggested associations between FT1DM and certain medications, warranting further investigation.
Objectives: This study aims to analyze drugs associated with an increased risk of FT1DM using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Therapeutic Effects of Tea Polyphenols on Renal Damage Induced by High Uric Acid.
Curr Med Chem
January 2025
Department of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Background: Hyperuricemia (HUA) is a condition characterized by excessive uric acid production and/or inadequate uric acid excretion due to abnormal purine metabolism in the human body. Uric acid deposits resulting from HUA can lead to complications such as renal damage. Currently, drugs used to treat HUA lack specificity and often come with specific toxic side effects.
View Article and Find Full Text PDFNew Pyranopyrazole-Based Indolin-2,3-dione Hybrid as Effective Inhibitors of Xanthine Oxidase: Synthesis, In Vitro, and Molecular Modelling Approaches.
Chem Biodivers
January 2025
Taibah University, Chemistry, Um alqara, Alula, SAUDI ARABIA.
In the current study, new pyranopyrazole analogues (9a-d and 10a-d) were synthesized through a one-pot condensation reaction of 2-arylacetohydrazide. The inhibitory abilities were investigated against the XO enzyme through experimental and molecular docking analyses. The synthesis studies were based on ultrasound-mediated condensation reactions of four-component systems containing 2-arylacetohydrazide, ethyl acetoacetate, indoline-2,3-dione, and ethyl 2-cyanoacetate/malononitrile in various solvents and catalysts to yield pyranopyrazole analogues (9a-d and 10a-d) in a short reaction time and remarkably favorable yields ranging from 79-92%.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!